Noteworthy SEC Filing: Boxer Capital Just Disclosed New Medicines Co De Position

Noteworthy SEC Filing: Boxer Capital Just Disclosed New Medicines Co De Position

The New Boxer Capital Holding in Medicines Co De

Boxer Capital filed with the SEC SC 13G form for Medicines Co De. The form can be accessed here: 000119312516775265. As reported in Boxer Capital’s form, the filler as of late owns 6% or 4,229,246 shares of the Health Care–company.

Medicines Co De stake is a new one for the and it was filed because of activity on November15, 2016. We feel this shows Boxer Capital’s positive view for the stock.

Medicines Co De Institutional Sentiment

Latest Security and Exchange filings show 175 investors own Medicines Co De. The institutional ownership in Q3 2015 is high, at 109.94% of the outstanding shares. This is increased by 5156545 the total institutional shares. 77828723 were the shares owned by these institutional investors. In total 35 funds opened new Medicines Co De stakes, 56 increased stakes. There were 27 that closed positions and 72 reduced them.

6 managers had the stock in their top Ten. Notable investors are: Antipodean Advisors Llc, Bridger Management Llc, Sarissa Capital Management Lp, Camber Capital Management Llc, Partner Investment Management L.P., Partner Fund Management L.P., Ashford Capital Management Inc, Signpost Capital Advisors Lp..

Ashford Capital Management Inc is an institutional investor bullish on Medicines Co De, owning 393144 shares as of Q3 2015 for 3.50% of its portfolio. Eric Chen Antipodean Advisors Llc owns 2438000 shares or 10.54% of its portfolio. MA Camber Capital Management Llc have 8.13% of their stock portfolio for 2500000 shares. Further, Sarissa Capital Management Lp reported stake worth 14.69% of its US stock portfolio. The NY Bridger Management Llc owns 2466205 shares. Medicines Co De is 6.39% of the manager’s US portfolio.

Business Profile

The Medicines Company is a global biopharmaceutical company. The Company’s marketed products include Angiomax (bivalirudin), Cleviprex (clevidipine) injectable emulsion, Ionsys (fentanyl iontophoretic transdermal system), Kengreal (cangrelor), Minocin (minocycline) for injection, and Orbactiv (oritavancin). Its pipeline of acute and intensive care hospital products in development include ABP-700, ALN-PCSsc, Carbavance and MDCO-216. It sells a ready to use formulation of Argatroban and has a portfolio of over 10 generic drugs, which is referred as acute care generic products. It sells over three acute care generic products, including midazolam, ondansetron and rocuronium. The Company’s products include Angiomax, which is a direct thrombin inhibitor; Cleviprex, which is a calcium channel blocker; Ionsys, which is a patient-controlled analgesia system; Kengreal, which is an antiplatelet agent; Minocin IV, which is a tetracycline-class antibiotic, and Orbactiv, which is an antibiotic.

SEC Form 13G is required when the filer owns between (5% and 20%) of a company and plans to hold it only as a passive investor. In case the filler intend to exert control and the stake’s exceeds 20%, then 13D Form must be filed. These filings can NOT be a precursor to “change of control” events such as hostile takeovers, company breakups or others.

Insitutional Activity: The institutional sentiment decreased to 1.16 in Q2 2016. Its down 0.11, from 1.27 in 2016Q1. The ratio is negative, as 20 funds sold all The Medicines Company shares owned while 54 reduced positions. 25 funds bought stakes while 69 increased positions. They now own 81.19 million shares or 0.45% less from 81.56 million shares in 2016Q1.

Prudential Financial, a New Jersey-based fund reported 176,091 shares. Wells Fargo And Mn holds 42,302 shares or 0% of its portfolio. Strs Ohio last reported 0% of its portfolio in the stock. Quantitative Management Lc has invested 0.01% of its portfolio in The Medicines Company (NASDAQ:MDCO). Cetera Advsr accumulated 10,550 shares or 0.03% of the stock. The New York-based Jennison Assoc Lc has invested 0.03% in The Medicines Company (NASDAQ:MDCO). Blackrock Inc holds 0% of its portfolio in The Medicines Company (NASDAQ:MDCO) for 7,348 shares. Everpoint Asset Mgmt Ltd Com owns 535,615 shares or 0.36% of their US portfolio. Dimensional Fund Advsr Lp accumulated 0.03% or 1.56 million shares. Jpmorgan Chase And, a New York-based fund reported 984,448 shares. Twin Focus Ptnrs Limited Com holds 0.69% or 26,000 shares in its portfolio. Steelhead Partners Limited Liability Company last reported 0.05% of its portfolio in the stock. Moreover, Brown Brothers Harriman & has 0% invested in The Medicines Company (NASDAQ:MDCO) for 83 shares. Moreover, Savings Bank Of America Corp De has 0% invested in The Medicines Company (NASDAQ:MDCO) for 84,110 shares. Wellington Management Group Llp last reported 9.80M shares in the company.

Insider Transactions: Since May 24, 2016, the stock had 2 insider purchases, and 4 insider sales for $1.75 million net activity. The insider MEANWELL CLIVE sold 20,000 shares worth $800,054. Shares for $2.00M were bought by Cox Christopher T on Tuesday, June 7. $555,000 worth of The Medicines Company (NASDAQ:MDCO) shares were sold by Spigelman Melvin K. Savage Robert G. sold $369,500 worth of The Medicines Company (NASDAQ:MDCO) on Tuesday, May 24.

The stock decreased 0.46% or $0.17 during the last trading session, hitting $36.71. About 1.07M shares traded hands. The Medicines Company (NASDAQ:MDCO) has risen 5.01% since April 20, 2016 and is uptrending. It has outperformed by 0.46% the S&P500.

The Medicines Company is a global biopharmaceutical company. The company has a market cap of $2.62 billion. The Company’s marketed products include Angiomax , Cleviprex (clevidipine) injectable emulsion, Ionsys (fentanyl iontophoretic transdermal system), Kengreal (cangrelor), Minocin (minocycline) for injection, and Orbactiv (oritavancin). It currently has negative earnings. The Company’s pipeline of acute and intensive care hospital products in development include ABP-700, ALN-PCSsc, Carbavance and MDCO-216.

The Medicines Company (NASDAQ:MDCO) Ratings Coverage

Out of 4 analysts covering The Medicines Co (NASDAQ:MDCO), 4 rate it a “Buy”, 0 “Sell”, while 0 “Hold”. This means 100% are positive. $65 is the highest target while $44 is the lowest. The $51.50 average target is 40.29% above today’s ($36.71) stock price. The Medicines Co has been the topic of 13 analyst reports since August 28, 2015 according to StockzIntelligence Inc. Chardan Capital Markets maintained the shares of MDCO in a report on Monday, March 21 with “Buy” rating. On Monday, August 31 the stock rating was maintained by RBC Capital Markets with “Outperform”. The firm has “Outperform” rating by RBC Capital Markets given on Wednesday, November 16. JP Morgan maintained The Medicines Company (NASDAQ:MDCO) on Saturday, August 29 with “Buy” rating. The rating was maintained by Oppenheimer on Monday, August 31 with “Market Perform”. The stock has “Outperform” rating given by RBC Capital Markets on Monday, November 16. On Monday, August 31 the stock rating was maintained by Leerink Swann with “Buy”. On Wednesday, November 4 the stock rating was initiated by Chardan Capital Markets with “Buy”. RBC Capital Markets maintained the stock with “Outperform” rating in Tuesday, November 8 report. On Friday, August 28 the stock rating was upgraded by Jefferies to “Hold”.

More important recent The Medicines Company (NASDAQ:MDCO) news were published by: Businesswire.com which released: “The Medicines Company and Alnylam Pharmaceuticals Present Positive Results …” on November 15, 2016, also Fiercebiotech.com published article titled: “The Medicines Company drops MDCO-216 as med comes up short”, Businesswire.com published: “Alnylam Pharmaceuticals and The Medicines Company Announce Publication of …” on November 13, 2016. More interesting news about The Medicines Company (NASDAQ:MDCO) was released by: Fool.com and their article: “Why The Medicines Company’s Share Price Got Sick Today” with publication date: October 06, 2016.

According to Zacks Investment Research, “Medicines Company acquires, develops and commercializes biopharmaceutical products in late stages of development. U.S. Food and Drug Administration intends to approve its first product, Angiomax, for use in the treatment of patients with unstable angina undergoing coronary balloon angioplasty. The company is also developing Angiomax for additional potential applications for use in the treatment of ischemic heart disease, a condition which occurs when organs receive an inadequate supply of oxygen as a result of decreased blood flow.”

MDCO Company Profile

The Medicines Company, incorporated on July 31, 1996, is a global biopharmaceutical company. The Company’s marketed products include Angiomax (bivalirudin), Cleviprex (clevidipine) injectable emulsion, Ionsys (fentanyl iontophoretic transdermal system), Kengreal (cangrelor), Minocin (minocycline) for injection, and Orbactiv (oritavancin). The Company’s pipeline of acute and intensive care hospital products in development include ABP-700, ALN-PCSsc, Carbavance and MDCO-216. The Firm sells a ready to use formulation of Argatroban and has a portfolio of over 10 generic drugs, which is referred as acute care generic products. The Firm sells over three of its acute care generic products, including midazolam, ondansetron and rocuronium.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.

Tags: , ,

Leave a Comment